CapsoVision, Inc.
CV
Get informed when a big investor buys or sells
+ FollowMarket Cap$296.28M
Close$
$-2.17
136.3% downside
Current Fair Value
136.3% downsideOvervalued by 136.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $296.28 Million |
|---|---|
| Enterprise Value | $288.03 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.54 |
| Beta | -2.37 |
| Outstanding Shares | 49,937,525 |
Return
| Return on Equity | -226.56% |
|---|---|
| Return on Assets | -160.64% |
| Return on Invested Capital | -150.08% |
Valuation & Multiples
| P/E Ratio | -9.41 |
|---|---|
| PEG | -15.24 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 20.74 |
| Enterprise Value to EBIT | -14.31 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$3.81 M
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
$3.74 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 8.42%▲ 6.80% |
|---|---|
| Total Invested | $29.12M▲ 255.22% |
| Investors Holding | 50▲ 19.00% |
ESG Score
No data
About CapsoVision, Inc.
90 employees
CEO: Kang Huai Wang Medical‑technology company developing advanced capsule endoscopy systems (CapsoCam Plus, CapsoCam Colon) and AI-enabled imaging platforms for gastrointestinal diagnostics